Drug profile · INN
seladelpar lysine
LIVDELZI
seladelpar lysine (LIVDELZI) is a peroxisome proliferator-activated receptor delta agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — seladelpar lysine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
seladelpar lysine (LIVDELZI) is a peroxisome proliferator-activated receptor delta agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Peroxisome proliferator-activated receptor delta agonist
Primary target: Peroxisome proliferator-activated receptor delta
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is seladelpar lysine?
seladelpar lysine (LIVDELZI) is a peroxisome proliferator-activated receptor delta agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for seladelpar lysine?
LIVDELZI is a marketed brand name for seladelpar lysine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of seladelpar lysine?
seladelpar lysine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.